Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121410 | 0.84 | APOBEC3G (1.00) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL7022399 | 0.80 | APOBEC3G (0.67) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL7783984 | 0.80 | APOBEC3G (0.67) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL21326159 | 0.80 | APOBEC3G (0.67) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL141091 | 0.78 | APOBEC3G (0.64) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| Ammonia Solution, Strong SCHEMBL28363215 | 0.77 | APOBEC3G (0.61) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL5556360 | 0.77 | APOBEC3G (0.61) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL28559827 | 0.77 | APOBEC3G (0.61) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL13284490 | 0.77 | APOBEC3G (0.75) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 | |
| SCHEMBL28021486 | 0.77 | APOBEC3G (0.61) | APOBEC3GALDH1A1TDP1HSD17B10HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923911-B1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2023-07-12 | — | — | EP | claimed |
| EP-3426254-B1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2023-06-07 | — | — | EP | claimed |
| EP-3923911-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | Lutris Pharma Ltd. (IL) | 2021-12-22 | — | — | EP | claimed |
| US-11197861-B2 | Methods of screening BRaf inhibitors for treating cutaneous reactions | LUTRIS PHARMA LTD. (IL) | 2021-12-14 | — | — | US | claimed |
| US-20210346389-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2021-11-11 | — | — | US | claimed |
| WO-2020165755-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD. (IL) | 2020-08-20 | — | — | WO | claimed |
| EP-3664849-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | Memorial Sloan-Kettering Cancer Center (US) | 2020-06-17 | — | — | EP | claimed |
| US-20200163967-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-28 | — | — | US | claimed |
| US-20200147090-A1 | METHODS OF SCREENING BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2020-05-14 | — | — | US | claimed |
| US-20190262343-A1 | WOUND HEALING USING BRAF INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | claimed |
| WO-2019032717-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-14 | — | — | WO | claimed |
| EP-3426254-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | Lutris Pharma Ltd. (IL) | 2019-01-16 | — | — | EP | claimed |
| US-20180369247-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD. (IL) | 2018-12-27 | — | — | US | claimed |
| WO-2017223245-A1 | WOUND HEALING USING BRAF INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-28 | — | — | WO | claimed |
| WO-2017154001-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD. (IL) | 2017-09-14 | — | — | WO | claimed |
| US-20170100345-A1 | WOUND HEALING USING BRAF INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | claimed |
| EP-3139927-A1 | WOUND HEALING USING BRAF INHIBITORS | The Regents of The University of California (US) | 2017-03-15 | — | — | EP | claimed |
| WO-2015171833-A1 | WOUND HEALING USING BRAF INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-12 | — | — | WO | claimed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | claimed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262343-A1 | WOUND HEALING USING BRAF INHIBITORS | BRAF, NRAS, RAF1 | APOBEC3G 1616/4885ALDH1A1 939/4885TDP1 1052/4885 |
| US-20170100345-A1 | WOUND HEALING USING BRAF INHIBITORS | BRAF, NRAS, RAF1 | APOBEC3G 1616/4885ALDH1A1 939/4885TDP1 1052/4885 |
| US-20210346389-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | BRAF, NRAS, RAF1 | APOBEC3G 825/4885ALDH1A1 1136/4885TDP1 253/4885 |
| US-11197861-B2 | Methods of screening BRaf inhibitors for treating cutaneous reactions | BRAF, EGFR, ERBB2 | APOBEC3G 955/4885ALDH1A1 1740/4885TDP1 1933/4885 |
| US-20180369247-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | BRAF, ERBB3, PIK3C3 | APOBEC3G 1376/4885ALDH1A1 1969/4885TDP1 1823/4885 |
| US-20200147090-A1 | METHODS OF SCREENING BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | BRAF, EGFR, ERBB2 | APOBEC3G 955/4885ALDH1A1 1740/4885TDP1 1933/4885 |
| US-20200163967-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | BRAF, NRAS, RAF1 | APOBEC3G 710/4885ALDH1A1 1888/4885TDP1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.